Login Register Cart 0
Generic placeholder image

Drug Metabolism and Bioanalysis Letters

Editor-in-Chief

ISSN (Print): 2949-6810
ISSN (Online): 2949-6829

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Investigation of Human in vivo Metabolism of SEP-227900 Using the Samples from First-in-Human Study by LC-HRMS/UV and NMR

Author(s): Yu-Luan Chen*, Estela Skende, Armand Gatien Ngounou Wetie and Peter Li-Quan Wang

Volume 15, Issue 1, 2022

Published on: 26 April, 2022

Page: [38 - 50] Pages: 13

DOI: 10.2174/1872312815666220302161959

Price: $65

Abstract

Objective: The study aims to explore the human in vivo metabolism of SEP-227900 (4H-furo[3, 2-b] pyrrole-carboxylic acid, m.w 151.03), a D-amino-acid oxidase (DAAO) inhibitor, by using plasma and urine samples from first-in-human study.

Methods: The human plasma and urine samples were from a single dose cohort that consisted of 9 healthy male volunteers each received an 80- mg dose of SEP-227900 orally. The pooled pre-dose urine and the pooled 0-24 h urine sample were created across 9 subjects by equal volume. Plasma samples were pooled by equal volume across 9 subjects to obtain 0-12 h plasma for metabolite searching, and also pooled by timepoints across 9 subjects to obtain 0.5, 5, and 12-h plasma for semi-quantitation. The plasma was de-proteinized by acetonitrile (1:3 v/v plasma-acetonitrile), then the supernatant was dried down, reconstituted, and injected for LC-HRMS/UV analysis. The urine sample was just simply centrifuged before analysis. LC-HRMS/UV was utilized to search predictable and unknown metabolites and estimate their relative abundances. Accurate mass measurement by Orbitrap-MS and MS/MS was used for metabolite identification. Chromatographic separation was achieved on a MACMOD AQ C8 column (250 × 4.6 mm, 5-μm) with a gradient mobile phase (A: 10 mM NH4Ac; B: acetonitrile; flowrate: 0.700 ml/min) for a total run-time of 65 min. The definite position in the molecule for the glucuronidation metabolism was characterized by the detected migration phenomenon, methylation with diazomethane (CH2N2), and NMR.

Results: Unchanged parent drug and four metabolite peaks were detected in humans: M1 was a mono-oxidative metabolite of SEP-227900; M2 was a glucuronide conjugate of SEP-227900; M3 was a glycine conjugate of SEP-227900; M4 was a glycine conjugate of M1. The specific position of the oxidation in M1 solely based on the mass spectral (MS and MS/MS) data was not identified. However, for the major metabolite M2, the acyl glucuronidation was unambiguously determined through multiple pieces of experimental evidence such as the observation of a migration pattern, mono-methylation by diazomethane, and NMR measurement. This determination is of significance related to the safety evaluation of investigational new drug development. The glycine conjugate of SEP-227900, i.e., M3, was found to be the most abundant metabolite in human urine (approximately 3-fold higher level than the glucuronide level). All together (mainly glycine-conjugate and glucuronide), it resulted in greater than 80% of the dosed amount in urine excretion (a separate measurement showed 23% of the dosed amount in urine excretion as the glucuronide).

Conclusion: Four metabolites were found in humans: SEP-227900-glycine conjugate, SEP- 227900-glucuronide, mono-oxidative metabolite, and its consequent glycine conjugate. The glucuronide metabolite was identified as acyl glucuronide. Greater than 80% of the dosed amount of SEP-227900 was excreted in the urine, mainly in the forms of glycine- and glucuronide- conjugates.

Keywords: SEP-227900, D-amino-acid oxidase (DAAO) inhibitor, drug metabolism, acyl glucuronide, LC-HRMS/UV, NMR.

« Previous Next »
Graphical Abstract

[1]
Cruccu, G.; Truini, A. A review of neuropathic pain: From guidelines to clinical practice. Pain Ther., 2017, 6(Suppl. 1), 35-42.
[http://dx.doi.org/10.1007/s40122-017-0087-0] [PMID: 29178033]
[2]
Gilron, I.; Watson, C.P.; Cahill, C.M.; Moulin, D.E. Neuropathic pain: A practical guide for the clinician. CMAJ, 2006, 175(3), 265-275.
[http://dx.doi.org/10.1503/cmaj.060146] [PMID: 16880448]
[3]
Barrett, A.M.; Lucero, M.A.; Le, T.; Robinson, R.L.; Dworkin, R.H.; Chappell, A.S. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review. Pain Med., 2007, 8(8)(Suppl. 2), S50-S62.
[http://dx.doi.org/10.1111/j.1526-4637.2006.00179.x] [PMID: 17714116]
[4]
Collins, S.D.; Chessell, I.P. Emerging therapies for neuropathic pain. Expert Opin. Emerg. Drugs, 2005, 10(1), 95-108.
[http://dx.doi.org/10.1517/14728214.10.1.95] [PMID: 15757406]
[5]
Rice, A.S.; Hill, R.G. New treatments for neuropathic pain. Annu. Rev. Med., 2006, 57, 535-551.
[http://dx.doi.org/10.1146/annurev.med.57.121304.131324] [PMID: 16409165]
[6]
Wallace, J.M. Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr. Pain Headache Rep., 2007, 11(3), 208-214.
[http://dx.doi.org/10.1007/s11916-007-0192-6] [PMID: 17504648]
[7]
Jensen, M.P.; Chodroff, M.J.; Dworkin, R.H. The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology, 2007, 68(15), 1178-1182.
[http://dx.doi.org/10.1212/01.wnl.0000259085.61898.9e] [PMID: 17420400]
[8]
Dickenson, A.H.; Chapman, V.; Green, G.M. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmis-sion and modulation of pain in the spinal cord. Gen. Pharmacol., 1997, 28(5), 633-638.
[http://dx.doi.org/10.1016/S0306-3623(96)00359-X] [PMID: 9184794]
[9]
Guo, J.D.; Wang, H.; Zhang, Y.Q.; Zhao, Z.Q. Distinct effects of D-serine on spinal nociceptive responses in normal and carrageenan-injected rats. Biochem. Biophys. Res. Commun., 2006, 343(2), 401-406.
[http://dx.doi.org/10.1016/j.bbrc.2006.02.156] [PMID: 16546123]
[10]
U.S. Food & Drug Administration. Guidances (Drugs). 2020. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
[11]
Bailey, M.J.; Dickinson, R.G. Acyl glucuronide reactivity in perspective: Biological consequences. Chem. Biol. Interact., 2003, 145(2), 117-137.
[http://dx.doi.org/10.1016/S0009-2797(03)00020-6] [PMID: 12686489]
[12]
Spahn-Langguth, H.; Benet, L.Z. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev., 1992, 24(1), 5-47.
[http://dx.doi.org/10.3109/03602539208996289] [PMID: 1555494]
[13]
Shipkova, M.; Armstrong, V.W.; Oellerich, M.; Wieland, E. Acyl glucuronide drug metabolites: Toxicological and analytical implications. Ther. Drug Monit., 2003, 25(1), 1-16.
[http://dx.doi.org/10.1097/00007691-200302000-00001] [PMID: 12548138]
[14]
Iwamura, A.; Nakajima, M.; Oda, S.; Yokoi, T. Toxicological potential of acyl glucuronides and its assessment. Drug Metab. Pharmacokinet., 2017, 32(1), 2-11.
[http://dx.doi.org/10.1016/j.dmpk.2016.11.002] [PMID: 28017536]
[15]
Van Vleet, T.R.; Liu, H.; Lee, A.; Blomme, E.A.G. Acyl glucuronide metabolites: Implications for drug safety assessment. Toxicol. Lett., 2017, 272, 1-7.
[http://dx.doi.org/10.1016/j.toxlet.2017.03.003] [PMID: 28286018]
[16]
Zhong, S.; Jones, R.; Lu, W.; Schadt, S.; Ottaviani, G. A new rapid in vitro assay for assessing reactivity of acyl glucuronides. Drug Metab. Dispos., 2015, 43(11), 1711-1717.
[http://dx.doi.org/10.1124/dmd.115.066159] [PMID: 26276581]
[17]
Compernolle, F.; Jansen, F.H.; Heirwegh, K.P.M. Mass-spectrometric study of the azopigments obtained from bile pigments with diazo-tized ethyl anthranilate. Biochem. J., 1970, 120(4), 891-894.
[http://dx.doi.org/10.1042/bj1200891] [PMID: 5500354]
[18]
Philipp, A.A.; Wissenbach, D.K.; Zoerntlein, S.W.; Klein, O.N.; Kanogsunthornrat, J.; Maurer, H.H. Studies on the metabolism of mi-tragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spec-trometry. J. Mass Spectrom., 2009, 44(8), 1249-1261.
[http://dx.doi.org/10.1002/jms.1607] [PMID: 19536806]
[19]
Faed, E.M. Properties of acyl glucuronides: Implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev., 1984, 15(5-6), 1213-1249.
[http://dx.doi.org/10.3109/03602538409033562] [PMID: 6396057]
[20]
Shitara, Y.; Hirano, M.; Sato, H.; Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther., 2004, 311(1), 228-236.
[http://dx.doi.org/10.1124/jpet.104.068536] [PMID: 15194707]
[21]
Tornio, A.; Filppula, A.M.; Kailari, O.; Neuvonen, M.; Nyrönen, T.H.; Tapaninen, T.; Neuvonen, P.J.; Niemi, M.; Backman, J.T. Glucu-ronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: A phase II metabolite as a perpetrator of drug-drug inter-actions. Clin. Pharmacol. Ther., 2014, 96(4), 498-507.
[http://dx.doi.org/10.1038/clpt.2014.141] [PMID: 24971633]
[22]
el Mouelhi, M.; Beck, S.; Bock, K.W. Stereoselective glucuronidation of (R)- and (S)-naproxen by recombinant rat phenol UDP-glucuronosyltransferase (UGT1A1) and its human orthologue. Biochem. Pharmacol., 1993, 46(7), 1298-1300.
[http://dx.doi.org/10.1016/0006-2952(93)90480-K] [PMID: 8216382]
[23]
Fujiwara, R.; Yoda, E.; Tukey, R.H. Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans. Drug Metab. Pharmacokinet., 2018, 33(1), 9-16.
[http://dx.doi.org/10.1016/j.dmpk.2017.10.002] [PMID: 29079228]
[24]
Badenhorst, C.P.; van der Sluis, R.; Erasmus, E.; van Dijk, A.A. Glycine conjugation: Importance in metabolism, the role of glycine N-acyltransferase, and factors that influence interindividual variation. Expert Opin. Drug Metab. Toxicol., 2013, 9(9), 1139-1153.
[http://dx.doi.org/10.1517/17425255.2013.796929] [PMID: 23650932]
[25]
Skende, E.; Shi, L.; Zheng, N.; Chen, Y-L. Direct quantitation of D-serine in human plasma by enantioselective liquid chromatography with tandem mass spectrometry and its application to a clinical study. J. Appl. Bioanal., 2019, 5(2), 20-33.
[http://dx.doi.org/10.17145/jab.19.005]
[26]
Knezevic, N.N.; Cicmil, N.; Knezevic, I.; Candido, K.D. Discontinued neuropathic pain therapy between 2009-2015. Expert Opin. Investig. Drugs, 2015, 24(12), 1631-1646.
[http://dx.doi.org/10.1517/13543784.2015.1099627] [PMID: 26472477]
[27]
Hamilton, R.A.; Garnett, W.R.; Kline, B.J. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin. Pharmacol. Ther., 1981, 29(3), 408-413.
[http://dx.doi.org/10.1038/clpt.1981.56] [PMID: 6781809]
[28]
Hop, C.E.C.A.; Wang, Z.; Chen, Q.; Kwei, G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J. Pharm. Sci., 1998, 87(7), 901-903.
[http://dx.doi.org/10.1021/js970486q] [PMID: 9649361]
[29]
Chen, Y-L.; Skende, E.; Lin, J.; Yi, Y.; Wang, P.L.; Wills, S.; Wilkinson, H.S.; Koblan, K.S.; Hopkins, S.C. Absorption, distribution, me-tabolism, and excretion of [14C]-dasotraline in humans. Pharmacol. Res. Perspect., 2016, 5(1), e00281.
[http://dx.doi.org/10.1002/prp2.281] [PMID: 28596833]

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy